journal
MENU ▼
Read by QxMD icon Read
search

Recent Patents on Anti-cancer Drug Discovery

journal
https://www.readbyqxmd.com/read/30027855/amplified-crosstalk-between-estrogen-binding-and-gfr-signaling-mediated-pathways-of-er-activation-drives-responses-in-tumors-treated-with-endocrine-disruptors
#1
Zsuzsanna Suba
BACKGROUND: The pharmaceutical development of endocrine disruptors could not achieve appropriate advances in the field of anticancer fight. OBJECTIVE: Considerations on the principles of currently used endocrine therapies. METHODS: Comparison of the results of genetic studies being performed on breast cancer cells treated with estrogens, synthetic estrogens and antiestrogens. RESULTS: In breast cancer cells, increased estrogen concentrations amplify ER-signaling via a synergistic upregulation of both liganded and unliganded ER-activations and increased aromatase expression...
July 20, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29956637/cs5931-a-novel-marine-polypeptide-inhibits-migration-and-invasion-of-cancer-cells-via-interacting-with-enolase-1
#2
Shuonan Su, Huanli Xu, Xiaoliang Chen, Gan Qiao, Ammad Ahamd Farooqi, Ye Tian, Ru Yuan, Xiaohui Liu, Cong Li, Xiao Li, Ning Wu, Xiukun Lin
BACKGROUND: CS5931, a novel marine peptide (Patent number, CN102172394B), was extracted and purified from the sea squirt Ciona savignyi. Our previous studies showed that recombinant CS5931 can significantly inhibit tumor growth both in vitro and in vivo. OBJECTIVE: This study aimed to investigate the effects of the recombinant CS5931 on migration and invasion of cancer cells and the molecular targets. METHODS: The target of the recombinant CS5931 was identified by pull-down/SDS-PAGE/MS approaches and confirmed by Western blot and surface plasmin resonance analysis...
June 28, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29807523/targeting-metabolism-to-counteract-tumor-angiogenesis-a-review-of-patent-literature
#3
Sara Petrillo, Emanuela Tolosano, Luca Munaron, Tullio Genova
Massive vessel recruitment is required to sustain rapid tumor growth by delivering oxygen and nutrients. Current strategies to counteract angiogenesis are mostly aimed at reducing tumor vessel density. However, many of these drugs have been shown to trigger hypoxia, thus exacerbating tumor aggressiveness. Promising results come from a completely different approach based on the "normalization" of the endothelial layer and the consequent improvement of the vascular function. Since endothelial metabolism has proved essential in the regulation of the angiogenic switch, many recent patents focus on agents able to inhibit specific metabolic pathways in tumor-associated endothelial cells (TECs) in order to provide vessel normalization...
May 27, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29769012/synthesis-in-silico-and-in-vitro-cytostatic-activity-of-new-lipophilic-derivatives-of-hydroxyurea
#4
Zeynab Khansepid, Asghar Davood, Maryam Iman, Mahdi Fasihi Ramandi
BACKGROUND: Hydroxyurea (HU) is used to treat cancer., HU has a short half-life due to its small molecular weight and high polarity, therefore a high dosage of the drug should be used which introduces side effects and more rapid development of resistance. OBJECTIVE: The objective of the current study is to design a new lipophilic analogues of hydroxyurea with higher stability and better cell penetration. Then Tthe designed compoundsdrug wereas synthesized and then evaluated in terms of theirthe cytostatic activiactivitiesty was evaluated against two human cell linesthe Panc and Hella cell lines...
May 16, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29769011/evolving-strategies-for-the-treatment-of-t-cell-lymphoma-a-systematic-review-and-recent-patents
#5
Kamel Laribi, Mustapha Alani, Catherine Truong, Alix Baugier de Materre
OBJECTIVE: Mature T-cell lymphomas are a heterogeneous group of T-cell malignancies with a poor outcome. The discovery of new molecular biomarkers has led to the emergence of new drugs in recent years that target various signaling pathways. METHOD: We examined all pertinent published patents through 2015 that analyzed novel methods for the diagnosis and treatment of T cell lymphoma, as well as related published and unpublished studies. Selection criteria were established before data collection...
May 16, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29708077/emerging-drugs-for-the-treatment-of-breast-cancer-brain-metastasis-a-review-of-patent-literature
#6
Maricruz Anaya-Ruiz, Cindy Bandala, Patricia Martinez-Morales, Gerardo Landeta, Rebeca D Martinez-Contreras, Nancy Martinez-Montiel, Martin Perez-Santos
BACKGROUND: Despite dramatic advances in cancer treatment that lead to long-term survival, there is an increasing number of patients presenting with clinical manifestations of cerebral metastasis in breast cancer, for whom only palliative treatment options exist. OBJECTIVE: The present review aims to provide to identify recent patens of breast cancer brain metastasis that may have application in improving cancer treatment. METHOD: Recent patents regarding the breast cancer brain metastasis were obtained from USPTO patent databases, Esp@cenet, Patentscope and Patent Inspiration®...
April 29, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29708076/recent-progress-of-marine-polypeptides-as-anticancer-agents
#7
Lanhong Zheng, Yixin Xua, Xiukun Lin, Zhixin Yuan, Minghua Liu, Shousong Cao, Fuming Zhang, Robert J Linhardt
BACKGROUND: Marine environment constitutes an almost infinite resource for novel anticancer drugs discovery. The biodiversity of marine organisms provides a rich source for the discovery and development of novel anticancer peptides in the treatment of human cancer. Marine peptides represent a new opportunity to obtain lead compounds in biomedical field, particularly for cancer therapy. OBJECTIVE: Providing an insight of the recent progress of patented marine peptides and presenting information about the structures and mechanistic mode of anticancer activities of these marine peptides...
April 29, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29676234/low-dose-of-acacetin-promotes-breast-cancer-mcf-7-cells-proliferation-through-the-activation-of-erk-pi3k-akt-signaling-pathway
#8
Huanhuan Ren, Jun Ma, Lingling Si, Boxue Ren, Xiaoyu Chen, Dan Wang, Wenjin Hao, Xuexi Tang, Defang Li, Qiusheng Zheng
Background Phytoestrogens has been proposed as a replaceable medicine for climacteric hormone replacement therapy, according to EP3138562, WO/2017/019213 and US5516528. However, recent studies showed that phytoestrogens might promote the proliferation of breast cancer cells and that is associated with their estrogenic activity. Acacetin, as one phytoestrogen, has been reported to exhibit estrogenic activity. But the effects of Acacetin on breast cancer cells proliferation have not been explored Objective In this study, we evaluated the effects of acacetin on breast cancer MCF-7 cells proliferation and explored its possible mechanism...
April 20, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29512471/tc-0-05-as-a-pharmacokinetic-parameter-of-paclitaxel-for-therapeutic-efficacy-and-toxicity-in-cancer-patients
#9
D S Xin, L Zhou, C Z Li, S Q Zhang, H Q Huang, G D Qiu, L F Lin, Y Q She, J T Zheng, C Chen, L Fang, Zhe-Sheng Chen, S Y Zhang
BACKGROUND: Paclitaxel (PTX) has remarkable anti-tumor activity, but it causes severe toxicities. There is an urgent need to seek an appropriate pharmacokinetic parameter of PTX to improve treatment efficacy and reduce adverse effects. OBJECTIVE: To evaluate the association of pharmacokinetic parameter TC>0.05 of paclitaxel (PTX) and its therapeutic efficacy and toxicity in patients with solid tumors. METHOD: A total of 295 patients with ovarian cancer, esophageal cancer, breast cancer, and non-small cell lung cancer (NSCLC), who were admitted to the Tumor Hospital of Shantou University Medical College, China, were recruited for this study...
March 5, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29512470/parp-inhibitors-in-ovarian-cancer
#10
Gloria Mittica, Eleonora Ghisoni, Gaia Giannone, Sofia Genta, Massimo Aglietta, Anna Sapino, Giorgio Valabrega
BACKGROUND: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients. OBJECTIVES: To highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis...
March 5, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29512469/stemness-phenotype-in-tamoxifen-resistant-breast-cancer-cells-may-be-induced-by-interactions-between-receptor-tyrosine-kinases-and-er%C3%AE-66
#11
Leila Farahmand, Sepideh Mansouri, Narges Jafarbeik-Iravani, Azin Teymourzadeh, Keivan Majidzadeh-A
BACKGROUND: Tamoxifen is widely administered for patients with estrogen receptor-positive breast cancer. Despite many metastatic cancer patients benefiting from Tamoxifen as an effective anti-hormonal agent in adjuvant therapy, a noticeable number of patients tend to develop resistance. As a result, forming effective approaches in the successful treatment of Tamoxifen resistance in relation to breast cancer requires a comprehensive understanding of the complex signaling pathways and their underlying crosstalks involved...
March 5, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29485010/the-application-of-lncrnas-in-cancer-treatment-and-diagnosis
#12
Yi Zhang, Liling Tang
BACKGROUND: It is increasingly evident that lncRNAs have various biological functions playing as essential regulators, getting involved in diverse cellular processes. Many of lncRNAs show aberrant expression in cancer, which is associated with different cancer types. The dysregulation of lncRNAs has been increasingly linked to cancer carcinogenesis and progression. OBJECTIVE: Due to their tissue-specific expression and key role in cancer, lncRNAs have the potential to be novel biomarkers or effective drug targets for cancer...
February 26, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29485009/oral-submucous-fibrosis-as-an-overhealing-wound-implications-in-malignant-transformation
#13
Mohit Sharma, Smitha Sammith Shetty, Raghu Radhakrishnan
BACKGROUND: Oral submucous fibrosis is an oral potentially malignant disorder with high incidence of malignant transformation and rising global prevalence. However, the genesis of oral submucous fibrosis is still unclear despite superfluity of literature. In the background of ineffective treatment, it is necessary to decode its onset and progression before designing customized treatment regimens. OBJECTIVE: The objective of this article is to decipher the pathogenesis of oral submucous fibrosis in order to identify novel drug targets...
February 26, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29788867/patent-selections
#14
(no author information available yet)
No abstract text is available yet for this article.
2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29600769/anti-cancer-effect-of-%C3%AE-solanine-by-down-regulating-s100p-expression-in-colorectal-cancer-cells
#15
Xiaofen Ni, Jiajun Chen, Fengying Lu, Zhengzhong Yuan, Xiaofeng Xu, Zhen Hu, Lei Jiang
BACKGROUND: α-Solanine, the most important and active component of Solanum nigrum, was found to have anti-cancer activity on multiple cancer cells. However, its effects on colorectal cancer (CRC) and associated molecular mechanisms remain to be further elucidated. OBJECTIVE: In this study, we investigated the anti-cancer effects of α-solanine against CRC cells in vitro and in vivo. MATERIALS & METHODS: Cell viability was measured using Cell Counting Kit-8 (CCK-8) assay; cell cycle was analyzed with a Cycletest Plus DNA Reagent Kit; cell apoptosis was detected by flow cytometer; cell migration and invasive ability was determined by Transwell assays; S100P protein expression was also analyzed by western blotting; lentiviral vectors expressing shRNA targeting the S100P gene...
2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29468983/synthesis-and-dft-study-on-hantzsch-reaction-to-produce-asymmetrical-compounds-of-1-4-dihydropyridine-derivatives-for-p-glycoprotein-inhibition-as-anticancer-agent
#16
Shirin Mollazadeh, Fatemeh Moosavi, Farzin Hadizadeh, Mahmoud Seifi, Javad Behravan, Maryam Iman
BACKGROUND: P-glycoprotein (P-gp) causes the efflux of cancer chemotherapy drugs from tumor cells, so its inhibition can be one target for designing and synthesis of new anticancer drugs. OBJECTIVE: In this study, new compounds of 1,4-dihydropyridine (DHP) were recommended as inhibitors of P-gp. METHODS: We synthesized new symmetrical DHP with 36% - 43% yield by the reaction of new reactants. In biological studies, these compounds have high lipophilicity, and thus low water solubility...
2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29468982/novel-patents-targeting-interleukin-17a-implications-in-cancer-and-inflammation
#17
Juan F Santibanez, Suncica Bjelica
BACKGROUND: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others...
2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29468981/lenvatinib-in-the-therapy-of-aggressive-thyroid-cancer-state-of-the-art-and-new-perspectives-with-patents-recently-applied
#18
Silvia M Ferrari, Ilaria Ruffilli, Marco Centanni, Camilla Virili, Gabriele Materazzi, Magdalini Alexopoulou, Mario Miccoli, Alessandro Antonelli, Poupak Fallahi
BACKGROUND AND OBJECTIVE: Lenvatinib is an oral, multitargeted Tyrosine Kinase Inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR1-VEGFR3), fibroblast growth factor receptors (FGFR1-FGFR4), Platelet-Derived Growth Factor Receptor (PDGFR)α, rearranged during transfection (RET), and v-kit (KIT) signaling networks implicated in tumor angiogenesis. METHOD: Here, we review the scientific literature about lenvatinib in the treatment of thyroid cancer...
2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29446748/anti-oxidants-as-chemopreventive-agents-in-prostate-cancer-a-gap-between-preclinical-and-clinical-studies
#19
Monireh Mohsenzadegan, Farhad Seif, Mohammad M Farajollahi, Majid Khoshmirsafa
BACKGROUND: Tumor cells may be expressed as a result of oxidative stress. The extent of oxidative stress correlates with the aggressive and metastatic potency of cancer. OBJECTIVE: One simple way to control prostate cancer is through chemoprevention which refers to the administration of natural or synthetic agents to block, reverse, or delay the process of carcinogenesis. The most chemopreventive agents are antioxidants in nature. METHODS: In this review, we summarized the effects of dietary antioxidants with a focus on their molecular mechanisms and possible roles in the treatment of prostate cancer cells...
2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29336268/anaplastic-lymphoma-kinase-in-glioblastoma-detection-diagnostic-methods-and-therapeutic-options
#20
Theodosis Kalamatianos, Despoina Denekou, George Stranjalis, Evangelia Papadimitriou
BACKGROUND: Glioblastoma (GBM) is the most aggressive and common brain tumor in adults, currently lacking effective life-prolonging and recurrence-preventing therapy; median survival of GBM patients stands at only 14-16 months. Increasing lines of evidence indicate that Anaplastic lymphoma kinase (ALK), a druggable tyrosine kinase receptor over-expressed in GBM, represents a potential therapeutic target in this tumor. OBJECTIVE: An overview of the state of the art and the existing recent patents regarding potential exploitation of ALK as a therapeutic target and/or diagnostic/prognostic factor in GBM...
2018: Recent Patents on Anti-cancer Drug Discovery
journal
journal
41278
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"